However, our study revealed that the abnormal LDH was associated with shorter PFS in advanced NSCLC patients treated with EGFR-TKI, suggesting that LDH may be an independent prognosis indicator for NSCLC instead of a predictive biomarker for immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.